XML 41 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

						For the Three Months Ended June 30, 2024
						Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Revenues:
Rental income						$	54,555					$	—					$	8,315					$	62,870
Residents fees and services						—						308,522						—						308,522
Total revenues						54,555						308,522						8,315						371,392
Expenses:
Property operating expenses						24,282						279,538						245						304,065
Depreciation and amortization						18,975						46,911						2,471						68,357
General and administrative						—						—						6,262						6,262
Acquisition and certain other transaction related costs						—						—						1,826						1,826
Impairment of assets						6,545						—						—						6,545
Total expenses						49,802						326,449						10,804						387,055
Loss on sale of properties						(13,213)						—						—						(13,213)
Interest and other income						—						—						2,403						2,403
Interest expense						(894)						(61)						(57,747)						(58,702)
Loss on modification or early extinguishment of debt						—						—						(209)						(209)
Loss before income tax expense and equity in net (losses) earnings of investees						(9,354)						(17,988)						(58,042)						(85,384)
Income tax expense						—						—						(170)						(170)
Equity in net (losses) earnings of investees						(21,493)						—						9,186						(12,307)
Net loss						$	(30,847)					$	(17,988)					$	(49,026)					$	(97,861)

						For the Six Months Ended June 30, 2024
						Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Revenues:
Rental income						$	108,704					$	—					$	16,816					$	125,520
Residents fees and services						—						616,648						—						616,648
Total revenues						108,704						616,648						16,816						742,168
Expenses:
Property operating expenses						48,179						562,954						536						611,669
Depreciation and amortization						39,715						93,833						4,942						138,490
General and administrative						—						—						13,830						13,830
Acquisition and certain other transaction related costs						—						—						1,912						1,912
Impairment of assets						18,687						—						—						18,687
Total expenses						106,581						656,787						21,220						784,588
Loss on sale of properties						(19,087)						—						—						(19,087)
Interest and other income						—						—						4,640						4,640
Interest expense						(1,116)						(129)						(115,033)						(116,278)
Loss on modification or early extinguishment of debt						—						—						(209)						(209)
Loss before income tax expense and equity in net (losses) earnings of investees						(18,080)						(40,268)						(115,006)						(173,354)
Income tax expense						—						—						(357)						(357)
Equity in net (losses) earnings of investees						(19,880)						—						9,471						(10,409)
Net loss						$	(37,960)					$	(40,268)					$	(105,892)					$	(184,120)

						As of June 30, 2024
						Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Total assets						$	1,778,781					$	3,103,090					$	451,576					$	5,333,447

						For the Three Months Ended June 30, 2023
						Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Revenues:
Rental income						$	53,368					$	—					$	8,005					$	61,373
Residents fees and services						—						284,846						—						284,846
Total revenues						53,368						284,846						8,005						346,219
Expenses:
Property operating expenses						23,938						261,959						331						286,228
Depreciation and amortization						22,855						43,152						2,387						68,394
General and administrative						—						—						7,284						7,284
Acquisition and certain other transaction related costs						—						—						6,043						6,043
Impairment of assets						11,299						—						—						11,299
Total expenses						58,092						305,111						16,045						379,248
Interest and other income						—						1,466						3,668						5,134
Interest expense						(116)						(152)						(47,116)						(47,384)
Loss before income tax expense and equity in net earnings of investees						(4,840)						(18,951)						(51,488)						(75,279)
Income tax expense						—						—						(221)						(221)
Equity in net earnings of investees						2,929						—						—						2,929
Net loss						$	(1,911)					$	(18,951)					$	(51,709)					$	(72,571)

						For the Six Months Ended June 30, 2023
						Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Revenues:
Rental income						$	110,390					$	—					$	17,421					$	127,811
Residents fees and services						—						564,438						—						564,438
Total revenues						110,390						564,438						17,421						692,249
Expenses:
Property operating expenses						47,453						524,288						567						572,308
Depreciation and amortization						42,890						85,304						5,000						133,194
General and administrative						—						—						13,157						13,157
Acquisition and certain other transaction related costs						—						—						6,136						6,136
Impairment of assets						13,607						3,617						—						17,224
Total expenses						103,950						613,209						24,860						742,019
Gain on sale of properties						—						1,233						—						1,233
Gains on equity securities, net						—						—						8,126						8,126
Interest and other income						—						1,466						7,863						9,329
Interest expense						(225)						(423)						(94,516)						(95,164)
Loss on modification or early extinguishment of debt						—						—						(1,075)						(1,075)
Income (loss) before income tax expense and equity in net earnings of investees						6,215						(46,495)						(87,041)						(127,321)
Income tax expense						—						—						(190)						(190)
Equity in net earnings of investees						2,282						—						—						2,282
Net income (loss)						$	8,497					$	(46,495)					$	(87,231)					$	(125,229)

			As of December 31, 2023
			Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Total assets			$	1,866,422					$	3,134,978					$	444,736					$	5,446,136

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration